Semi-Quantification of Myocardial Uptake of Bone-Seeking Agents in Suspected Cardiac Amyloidosis.
bone scan
bone scintigraphy
cardiac amyloidosis
quantification
transthyretin
Journal
Journal of cardiovascular development and disease
ISSN: 2308-3425
Titre abrégé: J Cardiovasc Dev Dis
Pays: Switzerland
ID NLM: 101651414
Informations de publication
Date de publication:
22 Apr 2023
22 Apr 2023
Historique:
received:
24
03
2023
revised:
14
04
2023
accepted:
19
04
2023
medline:
26
5
2023
pubmed:
26
5
2023
entrez:
26
5
2023
Statut:
epublish
Résumé
Bone scintigraphy has emerged as a key tool for non-invasive etiologic diagnosis of transthyretin (ATTR) cardiac amyloidosis (CA). We focused on a new semi-quantification method (on planar imaging) that could complement the qualitative/visual Perugini scoring system, especially when SPET/CT is not available. We retrospectively/qualitatively evaluated 8674 consecutive, planar 99mTc-biphosphonate scintigraphies (performed for non-cardiac reasons), identifying 68 (0.78%) individuals (mean age 79 ± 7 years, range 62-100 years; female/male ratio 16/52) presenting myocardial uptake. Due to the retrospective nature of the study, no SPET/CT, pathologic or genetic confirmation was obtained. The Perugini scoring system was determined (in patients presenting cardiac uptake) and compared with three newly proposed semi-quantitative indices. We took 349 consecutive bone scintigraphies, qualitatively absent of any cardiac/pulmonary uptake, as "healthy controls" (HC). The heart-to-thigh ratio (RHT) and lung-to-thigh ratio (RLT) indices were significantly higher in patients than in HCs (p ≤ 0.0001). There were statistically significant differences for RHT in HCs vs. patients with qualitative Perugini scores of 1 or >1 (with p ranging from ≤0.001 to ≤0.0001). ROC curves showed that RHT outperformed the other indices and was more accurate in both male and female groups. Furthermore, in the male population, RHT accurately distinguished HCs and patients with scores of 1 (less likely affected by ATTR) from patients with qualitative scores >1 (more likely affected by ATTR) with an AUC of 99% (sensitivity: 95%; specificity: 97%). The proposed semi-quantitative RHT index can accurately/semi-quantitatively distinguish between HCs and subjects probably affected by CA (Perugini scores from 1 to 3), and could be particularly useful when no SPET/CT data are available (such as in retrospective studies and data mining). Furthermore, RHT can semi-quantitatively predict, with very high accuracy, subjects in the male population more likely to be affected by ATTR. The present study, although using a very large sample, is however retrospective, monocentric, and therefore the generalizability of the results should be proved by an accurate external validation. The proposed heart-to-thigh ratio (RHT) can distinguish healthy controls and subjects that are probably affected by cardiac amyloidosis in a simple and more reproducible way, as compared to standard qualitative/visual evaluation.
Identifiants
pubmed: 37233151
pii: jcdd10050184
doi: 10.3390/jcdd10050184
pmc: PMC10218877
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Circulation. 2016 Jun 14;133(24):2404-12
pubmed: 27143678
Eur Heart J. 2023 Mar 22;:
pubmed: 36946431
J Nucl Cardiol. 2022 Dec;29(6):3419-3425
pubmed: 35437680
Heart Fail Rev. 2015 Mar;20(2):133-44
pubmed: 25549885
J Am Coll Cardiol. 2017 Jul 25;70(4):466-477
pubmed: 28728692
J Nucl Med. 2016 Nov;57(11):1733-1739
pubmed: 27307344
Curr Cardiol Rep. 2012 Apr;14(2):226-33
pubmed: 22193845
J Nucl Cardiol. 2019 Apr;26(2):497-504
pubmed: 28537040
BMC Bioinformatics. 2011 Mar 17;12:77
pubmed: 21414208
Eur Heart J Cardiovasc Imaging. 2014 Nov;15(11):1289-98
pubmed: 24939945
Cardiovasc Pathol. 2015 Nov-Dec;24(6):343-50
pubmed: 26361138
Blood Rev. 2017 Jul;31(4):261-270
pubmed: 28336182
JACC Cardiovasc Imaging. 2020 Jun;13(6):1314-1321
pubmed: 31864976
JACC Cardiovasc Imaging. 2020 Apr;13(4):909-920
pubmed: 31864973
Am J Cardiol. 1997 Jul 1;80(1):93-5
pubmed: 9205031
Eur Heart J Cardiovasc Imaging. 2012 Aug;13(8):680-9
pubmed: 22307866
J Am Coll Cardiol. 2013 Oct 15;62(16):e147-239
pubmed: 23747642
Neth Heart J. 2019 Nov;27(11):525-536
pubmed: 31359320
Clin Med (Lond). 2018 Apr 1;18(Suppl 2):s30-s35
pubmed: 29700090
Am Heart J. 2004 May;147(5):919-23
pubmed: 15131552
J Am Coll Cardiol. 2019 Jul 23;74(3):296-298
pubmed: 31319911
Amyloid. 2020 Sep;27(3):191-199
pubmed: 32400202
Eur J Nucl Med Mol Imaging. 2011 Mar;38(3):470-8
pubmed: 21069320
J Nucl Cardiol. 2018 Feb;25(1):217-222
pubmed: 27804073
Eur J Heart Fail. 2022 Dec;24(12):2342-2351
pubmed: 35509173
Amyloid. 2016 Sep;23(3):194-202
pubmed: 27647161
J Am Coll Cardiol. 2005 Sep 20;46(6):1076-84
pubmed: 16168294